Visualization of prescriptive algorithm: provider dashboard prototype.

Slides:

Advertisements

Similar presentations

Copyright © 2005 American Medical Association. All rights reserved.

Advertisements

Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2017 American Academy of Pediatrics.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Age based demographics of US Physicians

Diabetes hazard rates by number of visits with reported statin use.

A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

The risk of DR progression as related to mean HbA1c during DCCT

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

A: Kaplan-Meier estimate of time to first LLA

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Illustration of the causal inference scheme.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Adjusted annual percentage of quality indicators by prescription

ROGER S. MAZZE, Ph.D., CHRISTOPHER L. KROGH, M.D.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.

Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

An algorithm depicting the basic approach to the Charcot foot

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

HRs for prostate cancer by medication status.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.

The effect of PAD and infection on outcome of cast treatment

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Selection of DFU patients and non-DFU controls

Association of ISI with all-cause mortality as modeled by cubic spline, adjusted for age, sex, race, and study site, among 3,138 participants in the CHS.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

The Kaplan-Meier curves display the time to event for the primary outcome (A) and total mortality (B) during follow-up from randomization until the end.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Difference in average school grades between offspring born to women with type 1 diabetes and the matched control children, by maternal third trimester.

A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

Progression to micro- or macroalbuminuria.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Example of how quantitative variables displaying a nonhomogeneous risk in visual display were split in high- and low-risk categories. Example of how quantitative.

Plots of average estimated and measured GFR vs

A: Probability of retinopathy-free survival.

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Duration of treatment and intervals of radiographic and ctDNA response

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Incidences of transitions between glycemic states by 25-OHD level.

Changes in autoantibody titers and GADA IgG1–4 subclass distribution.

Relationships between species richness and temperature or latitude

Differences in the values of HbA1c variables between the retinopathy-positive and retinopathy-negative groups at year 20. Differences in the values of.

Genomic determinants of response to cytotoxic chemotherapy.

Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.

Manhattan plot of 11,628 m/z features comparing participants who developed incident T2D versus those who did not. Manhattan plot of 11,628 m/z features.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

Algorithm for management of the patient with pain because of DSPN

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Sensitivity and specificity of HbA1c, FPG, and 2hPG in identifying persons who developed diabetes within 10 years of screening among children and adolescents.

Presentation transcript:

Visualization of prescriptive algorithm: provider dashboard prototype. Visualization of prescriptive algorithm: provider dashboard prototype. This figure visualizes how the prescriptive algorithm can be used by providers for a single patient. A: Displays the algorithm’s treatment recommendation along with the predicted posttreatment HbA1c under that treatment. B: Depicts the mean, SD, and full distribution of posttreatment HbA1c outcomes for the most similar patient visits in the data set for each of the six regimens on this patient’s menu of options. In each subpanel in panel B, the posttreatment HbA1c level is on the horizontal axis, and the number of visits is on the vertical axis. The table in panel C presents basic information about the patient’s demographic and medical history. D: Depicts the history of diabetes progression and treatment for the patient, with date along the horizontal axis. The vertical axis of the top subpanel indicates various drug classes; the vertical axis of the bottom subpanel depicts HbA1c percentage. Dimitris Bertsimas et al. Dia Care 2017;40:210-217 ©2017 by American Diabetes Association